Information for authors
Published by: The Public Health Agency of Canada
Date published: February 24, 2022
ISSN: 1481-8531
Submit a manuscript
About CCDR
Browse
Updated February 24, 2022
On this page:
- Introduction
- What we are looking for
- How to prepare a manuscript for CCDR
- How to submit a manuscript to CCDR
- How manuscripts are reviewed and processed
- What happens when a manuscript is accepted
- How CCDR addresses errors, competing interests and authorship changes
- How to contact the editorial office
- References
Introduction
The Canada Communicable Disease Report (CCDR) is an open access, online, bilingual, peer-reviewed journal on infectious diseases published on the Government of Canada website by the Public Health Agency of Canada and is available through PudMed, PudMed Central and DOAJ. CCDR is published ten times a year. Subscribers receive an email notice featuring a hyperlinked table of contents after each new issue is released.
Objective and scope
The objective of CCDR is to advance the capacity to prevent, detect and mitigate the effects of infectious diseases in Canada and worldwide. Its readers include clinicians, public health professionals, researchers, teachers, students and others who are interested in infectious diseases. To do this, we publish authoritative and practical articles including surveillance reports, outbreak reports, original research, rapid communications, advisory committee statements and more.
Open access policy
CCDR adheres to the Directory of Open Access Journals (DOAJ) definition of open access: that users have the right to read, download, copy, distribute, print, search or link to the full text of all articlesFootnote 1. The journal does not charge article processing charges (APCs) or submission charges and is free of charge to all readers. As of January 2019 all articles in CCDR are published under the Creative Commons Attribution CC BY 4.0 licenseFootnote 2.
What we are looking for
CCDR welcomes submissions, from across Canada and elsewhere, of articles on infectious diseases that inform policy, program development and practice. CCDR follows the recommendations of the following organizations:
- Canada's Tri-Council (Policy Statement on Ethical Conduct on Research Involving Humans)Footnote 3
- Canadian Council of Animal Care GuidelinesFootnote 4
- Council of Scientific Editors (Scientific Style and Format)Footnote 5
- Directory of Open Access JournalsFootnote 1
- International Committee of Medical Journal Editors (ICMJE)Footnote 6
- Public Health Agency of Canada (Policy for the Publication of Scientific and Research Findings)
- Sex and Gender Equity in Research (SAGER) (Guidelines)Footnote 7
- The Treasury Board of Canada Secretariat (Policy on Official LanguagesFootnote 8 and Standard on Web Accessibility)Footnote 9
CCDR does not publish policy statements, with the exception of Advisory Committee statements. Authors retain the responsibility for the content of their articles and opinions expressed are not necessarily those of the Public Health Agency of Canada (PHAC).
Types of articles
CCDR publishes a wide variety of articles (Table 1). Word counts cover the main body of the text and do not include the abstract, tables or references. Author checklists for many article types have now been published. Other types of articles, such as conference summaries, may also be appropriate; consult the Editor-in-Chief (michel.deilgat@phac-aspc.gc.ca) prior to submission.
Type of article (word count) |
Description |
---|---|
CommentaryFootnote 10 (1,000−1,500 words) |
Addresses a stand-alone issue, setting forth strengths and arguments to support a point of view, as well as potential weaknesses and counter-arguments |
Epidemiologic study (1,500–2,000 words) |
Includes cohort and case-control studies on infectious diseases as per the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines |
Implementation scienceFootnote 11 (1,500–2,000 words) |
Describes an innovative process, policy or program designed to monitor or decrease the impact of an infectious disease and generally includes an evaluation of how it worked |
Eyewitness report (1,000−1,500 words) |
Provides a first-hand practice-based account and insights about the prevention, detection or management of an infectious disease |
Outbreak reportFootnote 12 (2,000–2,500 words) |
Provides information about an outbreak, summarizing its epidemiology, risk factors, associated morbidity and mortality, public health interventions and outcomes |
OverviewFootnote 13 (1,500–2,000 words) |
Summarizes content from many specialized articles or sources into one broadly scoped article or introduces a topic for those who may be reading about this topic outside their field of expertise |
Qualitative studiesFootnote 14 (2,000–2,500 words) |
Analyzes data from direct field observations, in-depth interviews and/or written documents to identify themes that generate hypotheses on complex phenomena |
Rapid communicationFootnote 15 (750−1,500 words) |
Provides a short, timely and authoritative report of an emerging or re-emerging infectious disease that typically includes the results of preliminary investigations and any interim clinical and public health recommendations |
Surveillance reportFootnote 16 (2,000−2,500 words) |
Summarizes the trends in the incidence or prevalence of an infectious disease in Canada and analyzes the changes |
Survey reportFootnote 17 (1,500−2,000 words) |
Identifies "what is" in a population based on self-reports and follows the Checklist for Reporting Results of Internet E-Surveys (CHERRIES) |
Systematic reviewFootnote 18 (2,000−2,500 words) |
Provides a review of the literature according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) |
Co-publications, or publishing the same article in two different places, may be considered when it meets the requirements of the ICMJEFootnote 19, especially when it is on a topic of public health importance and is directed to two different audiences. Contact the Editor-in-Chief (michel.deilgat@phac-aspc.gc.ca) to discuss this possibility prior to submission.
How to prepare a manuscript for CCDR
Articles are most likely to be read when they are written in a clear, logical and compelling fashion. Avoid jargon and minimize the use of abbreviations. CCDR encourages submission soon after a study is complete. Data should be no more than three years old.
Style and formatting requirements
Manuscripts may be submitted in either English or French and prepared with Microsoft Word (.docx). See Table 2 for additional style and formatting information. For information on how to structure your manuscript to increase logic and readability see: A guide to publishing scientific research in the health sciencesFootnote 20.
Item | Requirement |
---|---|
Title page |
|
Abstract |
|
Main text |
|
Information after the text |
|
References |
|
Tables and figures |
|
How to submit a manuscript to CCDR
Authors employed by a government organization are responsible for obtaining appropriate clearance for publication of their manuscript at the Director level (equivalent) prior to submission.
Manuscripts can be submitted online directly to CCDR at ccdr-rmtc@phac-aspc.gc.ca.
Provide assurances
Upon submission, the author will need to state that:
- The manuscript is original and is not a violation or infringement of any existing copyright or license
- The manuscript is not under consideration elsewhere
- All authors meet the definition of authorship as set out by the International Committee of Medical Journal Editors (ICMJE)Footnote 22
- Permission has been obtained from the copyright holder(s) if indicated, for the use of any third-party textual, graphic, artistic or other material
In addition the submitting author will need to submit a completed ICMJE Conflict of Interest FormFootnote 23 from every author on the manuscript.
Agree to a Creative Commons Attribution CC BY 4.0 license
Upon submission, authors will need to agree in writing that if their submission is accepted, it will be published under the Creative Commons Attribution CC BY 4.0 license. This means that the authors or their affiliated institutions will retain ownership of their copyright in the manuscript, but allow anyone to copy and redistribute the article in any medium or format, remix, transform and build upon the material, for any purpose, as long as appropriate credit is given, a link to the license is provided, and any changes are indicatedFootnote 2.
Authors will be invited to identify their Open Researcher and Contributor Identification or ORCID numberFootnote 24.
How manuscripts are reviewed and processed
All manuscripts submitted are routinely screened with iThenticate, an antiplagiarism software, and then assessed by the Editor-in-Chief for suitability. If suitable, it undergoes a double-blind peer review (reviewers do not know who the authors are; authors do not know who the reviewers are). Reviewers are sent a reviewer questionnaire that corresponds to the manuscript type and are asked to assess the manuscript based on a reviewer questionnaire and make suggestions for improvements. For each type of article, questions in the reviewer questionnaire match up with the corresponding items in the Author Checklist, creating clear and consistent guidance for both authors and reviewers.
When peer review is complete, an Editor analyses the manuscript and considers the reviewers' comments, then recommends to the Editor-in-Chief whether to accept the manuscript as is, request further revisions or decline the manuscript for publication. If revisions are indicated, the editor sends the reviewers' comments and any additional editorial comments to the corresponding author and invites him or her to revise the manuscript and provide a response to each of the comments. When the revised manuscript and response to comments are received, the Editor advises the Editor-in-Chief on whether to accept the manuscript, decline it, or request additional revisions. The corresponding author is notified by email of the editorial decision.
What happens when a manuscript is accepted
All manuscripts accepted for publication are copy-edited and further changes may be needed at that time. Once the copy-editing is completed, manuscripts are proofed, translated, formatted for desktop publishing and web-coded. Corresponding authors are sent a copy-edited, proofed and formatted version of their manuscript for a final quality check prior to desktop publishing and web-coding; if requested, authors may also review the translated version.
How CCDR addresses errors, competing interests and authorship changes
CCDR has a number of policies and best practices in place to deal with errors, misconduct, authorship changes and conflicts.
Correction notices
When an error or omission is identified following publication, the CCDR Editorial Coordinator (ccdr-rmtc@phac-aspc.gc.ca) should be notified promptly. Any changes made to the web-coded version and the PDF of published articles are identified as an Erratum in a subsequent issue of CCDR with an explanation of the nature of the correction and the date of the change.
Ethical oversight, competing interests and transparency
- The submitting author has to submit a completed ICMJE Conflict of Interest FormFootnote 6 from every author on the manuscript.
- Author(s) should not dishonestly manipulate peer-review or publication processes. As defined by the Committee on Publication Ethics (COPE)Footnote 25, examples of manipulation of the publication process include but are not limited to:
- Preventing or inappropriately influencing the independent assessment of a manuscript by an independent peer
- Inappropriately attributing authorship of a manuscript
- Publishing fabricated or plagiarised research
- Manipulating the peer review process
- Substituting a manuscript
- Allegations of misconduct are addressed based on the guidance developed by the Committee on Publication Ethics (COPE)Footnote 25.
Appeals and complaints
- Any concerns or complaints about the editorial process should be directed to the Editorial Coordinator (ccdr-rmtc@phac-aspc.gc.ca), and if not satisfactorily addressed, brought to the attention of the Editor-in-Chief (michel.deilgat@phac-aspc.gc.ca)
- The appeal process for editorial decisions includes the reassessment of the manuscript by either an Associate Editor or the Editor-in-Chief, and potentially an additional expert reviewer.
Authorship changes
To add an author during the editorial and production process, the corresponding author needs to send an email to the Editor-in-Chief explaining why this author was not included beforehand and how the author meets all four ICMJE requirements for authorship. All authors, including the additional author, should be cc'd on the email.
To remove an author during the editorial and production process, the corresponding author needs to send an email to the Editor-in-Chief explaining why this author should be excluded and the affected author needs to agree. All authors should be cc'd on the email.
If an author requests his or her name to be removed after publication, CCDR will assess this request based on COPE guidanceFootnote 25.
How to contact the editorial office
If you have any questions, feedback, or information you would like to share, please contact the Editor-in-Chief (michel.deilgat@phac-aspc.gc.ca) or the Editorial Coordinator (ccdr-rmtc@phac-aspc.gc.ca).
Page details
- Date modified: